Related Experiment Video

Updated: Apr 6, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

[CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER]

A K Nosov, A V Novik, A V Vorobiev

    Voprosy Onkologii
    |August 6, 2015
    PubMed

    Insights

    Cytoreductive nephrectomy in metastatic renal cell carcinoma is being evaluated in new trials. It remains unclear which patients will benefit from this surgical approach alongside targeted therapy.

    Area of Science:

    • Oncology
    • Surgical Oncology
    • Nephrology

    Context:

    • The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) is uncertain with the advent of targeted therapies.
    • Two major phase III trials, CARMENA and SURTIME, are investigating the efficacy of CN in mRCC patients.

    Purpose:

    • To evaluate the effectiveness of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.
    • To determine patient subgroups who may or may not benefit from cytoreductive nephrectomy.

    Summary:

    • Current understanding of cytoreductive nephrectomy's benefit in metastatic renal cell carcinoma is limited.
    • Ongoing phase III trials (CARMENA, SURTIME) aim to clarify the role of CN in the context of targeted therapy.
    • Identifying predictive factors for patient benefit from CN is a key objective.

    Impact:

    • Findings will inform clinical decision-making regarding the use of cytoreductive nephrectomy in mRCC.
    • This research could refine treatment guidelines for metastatic renal cell carcinoma.
    • Improved patient selection for cytoreductive nephrectomy may enhance outcomes and resource allocation.

    More Related Videos

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    14.4K
    Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

    Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

    Published on: February 8, 2020

    9.6K

    Related Concept Videos

    Kidney Transplant II: Surgical Procedure01:26

    Kidney Transplant II: Surgical Procedure

    Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
    815
    Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

    Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

    Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
    354